Many countries have formed regulatory sectors for implementing nanotechnology. For example, the Environmental Protection Agency (EPA) is the functional regulatory body for overseeing regulatory parameters in the United States, while the European Food Safety Authority (EFSA) oversees these regulations within the European Union [74].

An analytical research infrastructure by the name of QualityNano was formed for NM safety assessment, characterization, and initiation of reliable or reproducible approaches to nanometrol­ogy. This was the rst European initiative, nishing in 2015. It included the SOPs’ development procedure to address the possible risks of nanomaterials when they were being administered to the living systems. Assay reproducibility, the usage of correct positive and negative controls, and con­trols overdose delivery were the areas of focus for this research infrastructure [85].

Electrostatic complexation of nucleic acids in combination with cationic substances is the basis for the formulation of most NP- based systems designed for genome editing, as these systems are delivered intracellularly by utilizing mechanisms such as phagocytosis and receptor- mediated endo­cytosis [105]. Cationic substances help to give responsive properties to NPs, which are helpful for endosomal escape like for delivering nucleic acids, lipofectamine (a common transfection reagent) is utilized which comes under ionizable lipid- like materials [106, 107]. These systems are very ben­ecial towards the intracellular environment and can be stabilized to ensure endocytic uptake [108]. As DNA is the main target of interest for gene editing, two different approaches are employed to target the nucleus: the rst approach is to reduce the size of the particles so that they can easily enter the nuclear pore; the second approach is to make the particles functional so that they can be utilized after endosomal escape [109]. These particles can also be utilized to target some specic intracel­lular environments or organelles such as mitochondria [110]. There are some nanoparticles designed specically for this scenario which have enhanced mucus- penetrating properties, and which can be administered through oral routes. Improved penetration was demonstrated by those NPs that were smaller than the mucus mesh pores while some systems which employ hydrophilic coatings such as polyethylene oxide or PEG have also demonstrated positive penetration [111]. It was also demon­strated that PEGylation improved penetration the capability of the particles through cystic brosis mucus [112].

Polymeric nanoparticles are one of the most dependable nanocarriers to be under production and they fall into the category of nanostructured systems. They are designed with a diameter range of between 10 and 1000 nm. Synthetic biodegradable polymers are utilized to construct these nanopar­ticles, of which the most often cited is poly caprolactone (PCL). Because of some of its positive attributes, and because it has been approved, PCL is reported to be the polymer of choice. These attributes include biocompatibility and low commercial costs [113, 114].

One well- known case is that of an arthritis- treating herbal extract formulation based on nanopar­ticles. In this instance silver nanoparticles were added into the formulation to strengthen the extract’s anti- inammatory qualities. Positive outcomes which emerged from the initial preclinical studies related to there being signicant anti- inammatory effects with no apparent toxicity in animal mod­els. However, a wide number of participants in Phase 2 clinical studies reported adverse effects, such as skin discoloration, digestive issues and signs for systemic toxicity. Upon investigation, the scien­tists discovered that the body gradually became overloaded by the silver nanoparticles, resulting in argyria (a condition caused by an accumulation of silver in the body) as well as other harmful con­sequences. The signicance of this case demonstrates that an understanding of the biodistribution and excretion pathways of nanoparticles in the human body is essential. It also underlines the neces­sity for long- term toxicity studies.

Ethics guidelines for natural nanoparticles is one thing. However, ther is also a pressing need to establish guidelines related to manufactured nanomaterials such as plant- derived fullerenes and C60 carbon shells as these manufactured entities pose signicant risk to human health. This is because while the human body may possess modied and evolved biological mechanisms to deal with natural nanopar­ticles, they lack any such advanced biological defense mechanism against synthetic ones [84, 132].

Ethically, there are a range of opinions among different regulatory bodies regarding how to deal with nanomaterials. On one side, there are some regulatory bodies, such as the UK’s Royal Society and Royal Academy of Engineering, who proposed in 2004 that ‘’if products harbour nanomaterials as a form of ingredients, then they must undergo through comprehensive safety trials and should only be marketed for use when approved through the scientic advisory body’. Additionally, they also recommended that these nanomaterials should be regarded as toxic and hazardous and hence their neutralization should be carried out in waste streams generated by different laboratories and factories [133].

In this chapter we discussed the detailed safety assessment of nanoparticle- based herbal formula­tions, which highlights the potential to transform herbal therapy into nanoparticle- enhanced formu­lations by improved targeted delivery, bioavailability, and efcacy. However, these advantages come with unique safety issues that call for careful evaluation and regulatory oversight [125]. Firstly, the signicance of safety assessment is discussed in these formulations which highlights the potential benets and risks of these advanced formulations [124]. Preclinical safety assessment involves in vitro toxicity testing, in vivo animal studies, biodistribution, immunogenicity, biocompatibility, and pharmacokinetics. Before commencing the clinical trials, these studies provide a comprehensive understanding of how nanoparticles interact with biological systems [139]. The goal of toxicologi­cal proling is to gain a deeper understanding of the dose- response relationships, to identify and characterize potentially harmful compounds, and to carry out tests for mutagenicity, carcinoge­nicity, genotoxicity, and long- term toxicity. This analysis is important in assessing the long- term safety and possible harmful effects [140]. Clinical safety assessment is crucial to evaluate the side effects as well as to guarantee the long- term safety in human subjects [41]. Pharmacovigilance and post- market surveillance are considered as important components of ongoing safety monitoring which addresses any emerging risk over the course of a product’s lifecycle. The regulatory frame­work and guidelines provide a backbone necessary for risk assessment models, international and national standards and good manufacturing practices (GMP) [129]. Different case studies provide lessons from safety failures and highlight successful examples. These real- world incidents demon­strate the signicance of comprehensive safety reviews and impart knowledge for important lessons. Moreover, ensuring ethical procedures and maintaining the public condence is essential for the effective implementation of these technologies.